Monday Aug 25
Reasons To Accumulate Shares Of Novavax
NVAX has a technology platform for the development of multiple vaccines, a robust R&D budget, growing revenue, its own manufacturing capability, and trial results published in NEJM.
Fri Aug 22, 2014
Use Options For a Chance To Buy Novavax at a 31% Discount
Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Friday, the stock is now 10.3% higher than the offering price.
Sat Aug 16, 2014
Fri Aug 15, 2014
Buy An Unprofitable Company That Will Use Your Capital To Become Profitable
A company that is profitable enough to pay shareholders dividends and repurchase its own shares obviously doesn't need your capital, but may be a good place to deposit your cash.
Wed Aug 13, 2014
Citigroup Inc. Initiates Coverage on Novavax
The firm set a "buy" rating on the stock. Separately, analysts at FBR Capital Markets cut their price target on shares of Novavax from $11.00 to $10.00 in a research note on Thursday, August 7th.
Tue Aug 12, 2014
Short Interest in Novavax Expands By 6.2%
Shares of Novavax saw a significant increase in short interest during the month of July.
Thu Aug 07, 2014
Novavax to Present at the Wedbush Securities Life Sciences Management Access Conference
A live webcast link for the presentation will be available via the company's website at www.novavax.com under Investor Info/Events.
Wed Aug 06, 2014
Novavax, Inc. Reports Second-Quarter 2014 Financial Results
Novavax, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for the second quarter and six months ended June 30, 2014.
Wed Jul 30, 2014
Novavax, Inc. To Host Conference Call To Discuss Second Quarter 2014...
Novavax, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that it will report its financial results for the second quarter of 2014 on Wednesday, August 6, 2014, after market close.